← Eichor
Condition: Conversion Therapy Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Conversion Therapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Perioperative Risk of Immunotherapy Based Neoadjuvant and Conversion Therapy for Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Qilu Hospital of Shandong University · NCT06571396TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases
NA · 1 location(s) · Niguarda Hospital · NCT07607873Pilot Neurobehavioral Therapy for Functional Neurological Disorder
NA · 1 location(s) · Rhode Island Hospital · NCT06873698FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of P
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07012798A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Phase 2 · 1 location(s) · Zhejiang University · NCT05837052Conversion Therapy Plus Surgery and Radiotherapy for Retroperitoneal Nodal Metastases in Gastric Cancer
Phase 2 · 1 location(s) · Jinbo Yue · NCT07007182Conversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein T
Phase 2 · 1 location(s) · First Hospital of China Medical University · NCT07483359Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma
Phase N/A · 1 location(s) · Guangxi Medical University · NCT06405321The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Periton
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06597526Efficacy and Safety of Tislelizumab Plus Chemotherapy as Conversion Therapy in Unresectable Locally Advanced ESCC
Phase N/A · 1 location(s) · Shandong Provincial Hospital · NCT07549100Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
Phase 2 · 1 location(s) · Hebei Medical University Fourth Hospital · NCT06949111Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06041477Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer
Phase 2 · 1 location(s) · Beijing Friendship Hospital · NCT07353684First-in-Human Clinical Trial of STUP-001, an In Vivo Direct Cell Conversion Gene Therapy for AIS-A/B Chronic Spinal Cor
Phase 1/Phase 2 · 1 location(s) · Yonsei University · NCT06922890Combined HAIC, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma
Phase 2 · 1 location(s) · Tongji Hospital · NCT06192797Camrelizumab Combined With Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) as Conversion Therapy for Poten
Phase 2/Phase 3 · 2 location(s) · Shanghai Zhongshan Hospital · NCT06796803Surgery for Locally Unresectable Pancreatic Cancer
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07241663Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma
NA · 1 location(s) · Peking University Cancer Hospital & Institute · NCT04047953Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer
Phase 2 · 1 location(s) · Fudan University · NCT07194005Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Ade
Phase 1/Phase 2 · 4 location(s) · West China Hospital · NCT07072351Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients
Phase N/A · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06682156Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
Phase 2 · 1 location(s) · Peking Union Medical College Hospital · NCT06215651Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Phase 3 · 1 location(s) · Fudan University · NCT04687631A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advance
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07438106Efficacy and Safety Comparison Between Intensified Therapy and Conversion Therapy For Advanced HCC After Failure of Firs
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07501351Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
Phase N/A · 2 location(s) · Ze-yang Ding, MD · NCT05713994A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary H
Phase 2/Phase 3 · 139 location(s) · AbbVie · NCT06345339Biomarkers and Molecular Mechanism Study of Hepatocellular Carcinoma After Radical Resection and Conversion Therapy
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT06382103Physician Modified Endovascular Grafts for the Treatment of Elective, Symptomatic or Ruptured Juxtarenal Aortic Aneurysm
NA · 1 location(s) · Baystate Medical Center · NCT07019454Bump the Lump - Intervention for the Treatment of Globus Pharyngeus
NA · 1 location(s) · Wake Forest University Health Sciences · NCT06762444
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.